M&A Deal Summary

Crucell NV Acquires SBL Vaccine

On November 29, 2006, Crucell NV acquired life science company SBL Vaccine from 3i Private Equity for 39M EUR

Acquisition Highlights
  • This is Crucell NV’s 1st transaction in the Life Science sector.
  • This is Crucell NV’s largest (disclosed) transaction.
  • This is Crucell NV’s 1st transaction in Sweden.

M&A Deal Summary
Date 2006-11-29
Target SBL Vaccine
Sector Life Science
Buyer(s) Crucell NV
Sellers(s) 3i Private Equity
Deal Type Add-on Acquisition
Deal Value 39M EUR

Target

SBL Vaccine

Stockholm, Sweden
SBL Vaccine is specialized in the development, manufacture and marketing of vaccines and niche pharmaceuticals. SBL Vaccine is based in Stockholm, Sweden.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Crucell NV

Leiden, Netherlands
Category Company
Founded 2000
Sector Life Science
Employees1,300
DESCRIPTION

Crucell NV is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Sweden) 1 of 1
Year (2006) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

3i Private Equity

London, United Kingdom

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1945
PE ASSETS 16.7B GBP
Size Mega
Type Sector Agnostic
DESCRIPTION

3i Private Equity is the private equity arm of 3i Group, a publicly held, global investment firm focused on private equity and infrastructure investing. 3i Private Equity generally targets buyout and growth capital financings and looks for opportunities across Europe, North America, and Asia. The Firm's targeted transaction range is €100 to €500 million. Industries of interest include business services, healthcare, consumer, media, oil/gas & power, technology, and financial services. 3i Group was originally formed in 1945 and is based in London.

DEAL STATS #
Overall 51 of 194
Sector (Life Science) 2 of 5
Type (Add-on Acquisition) 12 of 61
Country (Sweden) 2 of 15
Year (2006) 19 of 26
Size (of disclosed) 66 of 78
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-11-06 Navayuga

Hyderabad, India

Navayuga is a multidisciplinary engineering and construction company, focused on the construction of Pile foundations, Diaphragm walls, Marine structures like Berths, Wharves and Jetties, special foundations, large diameter bored piles, ground improvement geo-techniques, industrial structures, roads, bridges, and Irrigation infrastructure; including multi-disciplinary Turnkey projects on EPC basis and infrastructure facilities on Build, Operate & Transfer (B.O.T) basis. Navayuga was founded in 1986 and is based in Hyderabad, India.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-11-30 Target Express Holdings

Newton-le-Willows, United Kingdom

Target Express provides a full range of premium parcel delivery services for customers throughout the UK, with its main focus on overnight timed deliveries.

Sell £210M
Mergr

Product

Company

Legal